Biomarkers, Tumor

"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.

Descriptor ID	D014408
MeSH Number(s)	D23.101.140
Concept/Terms	Biomarkers, Tumor Biomarkers, Tumor Tumor Biomarkers Markers, Biological Tumor Tumor Markers, Biological Markers, Tumor Metabolite Tumor Metabolite Markers Metabolite Markers, Tumor Marker, Tumor Metabolite Metabolite Marker, Tumor Tumor Metabolite Marker Tumor Markers, Biologic Biologic Tumor Markers Markers, Biologic Tumor Marker, Biologic Tumor Biologic Tumor Marker Tumor Marker, Biologic Biochemical Tumor Markers Markers, Biochemical Tumor Marker, Biochemical Tumor Biochemical Tumor Marker Tumor Marker, Biochemical Tumor Markers, Biochemical Carcinogen Markers Markers, Carcinogen Markers, Neoplasm Metabolite Neoplasm Metabolite Markers Marker, Neoplasm Metabolite Metabolite Marker, Neoplasm Neoplasm Metabolite Marker Metabolite Markers, Neoplasm Biological Tumor Markers Biological Tumor Marker Tumor Marker, Biological Marker, Biological Tumor Markers, Tumor Markers, Tumor Tumor Markers Biomarkers, Cancer Cancer Biomarkers

Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".

Chemicals and Drugs [D]
Biological Factors [D23]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]

Below are MeSH descriptors whose meaning is related to "Biomarkers, Tumor".

Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.

Bar chart showing 362 publications over 31 distinct years, with a maximum of 26 publications in 2014 and 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1996	1	1	2
1997	2	0	2
1998	2	0	2
1999	1	1	2
2000	0	2	2
2001	3	0	3
2002	5	3	8
2003	5	3	8
2004	6	8	14
2005	8	4	12
2006	4	4	8
2007	7	4	11
2008	9	8	17
2009	8	6	14
2010	7	5	12
2011	9	16	25
2012	10	8	18
2013	8	13	21
2014	18	8	26
2015	15	5	20
2016	10	12	22
2017	10	6	16
2018	12	6	18
2019	16	10	26
2020	10	8	18
2021	8	6	14
2022	0	5	5
2023	0	4	4
2024	6	3	9
2025	2	0	2

Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.

Simhal AK, Firestone RS, Oh JH, Avutu V, Norton L, Hultcrantz M, Usmani SZ, Maclachlan KH, Deasy JO. High WEE1 expression is independently linked to poor survival in multiple myeloma. Blood Cancer J. 2025 Feb 20; 15(1):22.

View in: PubMed
Nguyen THH, Vu GH, Nguyen TT, Nguyen TA, Tran VU, Vu LT, Nguyen GTH, Nguyen ND, Tran TH, Nguyen VTC, Nguyen TD, Nguyen TH, Vo DH, Van TTV, Do TT, Le MP, Huynh LAK, Nguyen DS, Tang HS, Nguyen HN, Phan MD, Giang H, Tu LN, Tran LS. Combination of Hotspot Mutations With Methylation and Fragmentomic Profiles to Enhance Multi-Cancer Early Detection. Cancer Med. 2025 Jan; 14(1):e70575.

View in: PubMed
Avelino ARM, Pulipati S, Jamouss K, Bhardwaj PV. Updates in Treatment of HER2-positive Metastatic Breast Cancer. Curr Treat Options Oncol. 2024 Dec; 25(12):1471-1481.

View in: PubMed
Babu S, Horowitz M, Delgado-Coka LA, Roa-Pe?a L, Akalin A, Escobar-Hoyos LF, Shroyer KR. Keratin 17 and A2ML1 are negative prognostic biomarkers in non-small cell lung cancer. Pathol Res Pract. 2024 Nov; 263:155643.

View in: PubMed
Kazandjian D, Diamond B, Papadimitriou M, Hill E, Sklavenitis-Pistofidis R, Ziccheddu B, Blaney P, Chojnacka M, Durante M, Maclachlan K, Young R, Usmani S, Davies F, Getz G, Ghobrial I, Korde N, Morgan G, Maura F, Landgren O. Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma. Clin Cancer Res. 2024 Oct 01; 30(19):4482-4490.

View in: PubMed
Karpinski P, Mendez-Pena JE, Wu CL, Akalin A, Cornejo KM, Hung YP, Hoang MP. POU4F3 Is a Sensitive and Specific Marker of Merkel Cell Carcinoma. Mod Pathol. 2025 Jan; 38(1):100627.

View in: PubMed
Delgado-Coka LA, Roa-Pe?a L, Babu S, Horowitz M, Petricoin EF, Matrisian LM, Blais EM, Marchenko N, Allard FD, Akalin A, Jiang W, Larson BK, Hendifar AE, Picozzi VJ, Choi M, Shroyer KR, Escobar-Hoyos LF. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. Am J Clin Pathol. 2024 Sep 03; 162(3):314-326.

View in: PubMed
Santarosa Vieira AG, da Silva LS, Albino da Silva EC, Laus AC, Faria TMV, van Helvoort Lengert A, Martins GE, de Oliveira MA, Reis RM, Lopes LF, Pinto MT. Comprehensive microRNA expression analysis of pediatric gonadal germ cell tumors: unveiling novel biomarkers and signatures. Mol Oncol. 2024 Jun; 18(6):1593-1607.

View in: PubMed
Repetto F, Perrino CM, Hirsch MS. Intratesticular Mullerian Serous Borderline Tumor With Microinvasion: A Rare Tumor and Review of the Literature. Int J Surg Pathol. 2024 Dec; 32(8):1567-1573.

View in: PubMed
Toner J, Gordon JAR, Greenyer H, Kaufman P, Stein JL, Stein GS, Lian JB. RUNX2 as a Prognostic Factor in Human Cancers. Crit Rev Eukaryot Gene Expr. 2024; 34(7):51-66.

View in: PubMed

People

Explore

Similar Concepts

Top Journals